RELATED CONTENT
NEWS
- NICE requests yet more information from Roche about Zelboraf for skin cancer
- Halaven's prospects in 2nd line breast cancer riding on upcoming data
- NICE turns down Avastin in recurrent advanced ovarian cancer
- Triple-negative salvage for Eisai's down-not-out eribulin in earlier breast cancer?
ANALYSIS
Other Informa Analysis
COMMENT
Other Informa Comment

